Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Reporting Period: Preliminary data as of December 31, 2025
This filing announces preliminary unaudited financial data and upcoming business milestones. The company has not yet completed its year-end financial close for 2025.
Key Financial Metrics
- Cash, Cash Equivalents, and Marketable Securities: Approximately $791 million as of December 31, 2025 (preliminary and unaudited).
- Revenue, Profit, Margins, and Debt: The filing text does not provide clear values for revenue, net income, operating margins, or debt levels.
- Liquidity: The $791 million cash position indicates strong liquidity, though the figure is subject to change upon final audit.
Material Changes and Unusual Items
The filing does not provide comparative data for the prior period to quantify material changes in financial metrics. The primary disclosure is the preliminary cash balance estimate, which is explicitly noted as unaudited and subject to revision during the final closing procedures.
Guidance, Outlook, and Management Commentary
- 2026 Objectives: Management announced recent achievements and key business objectives and milestones for 2026 (details contained in attached press release).
- Conference Participation: The company will participate in the 44th Annual J.P. Morgan Healthcare Conference starting January 12, 2026, with an investor presentation scheduled for January 14, 2026.
- Forward-Looking Statements: The company undertakes no obligation to update the preliminary cash estimate or the presentation materials attached to this filing.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and marketable securities balance in the upcoming Form 10-K for the year ended December 31, 2025.
- Review the attached press release (Exhibit 99.1) for specific details on 2026 business milestones not detailed in the 8-K text.
- Monitor the investor presentation materials (Exhibit 99.2) for updated strategic guidance and operational targets.
- Confirm that the preliminary $791 million figure has not been adjusted in subsequent filings prior to the 10-K release.